PFIZER INC Intangible Assets, Gross (Excluding Goodwill)
PFIZER INC (PFE) had Intangible Assets, Gross (Excluding Goodwill) of $121.98 billion as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Goodwill and Other
us-gaap:IntangibleAssetsGrossExcludingGoodwill · last filed 2026-08-04
- 2026-06-28: Intangible Assets, Gross (Excluding Goodwill) $121.98B.
- 2026-03-29: Intangible Assets, Gross (Excluding Goodwill) $126.42B.
- 2025-12-31: Intangible Assets, Gross (Excluding Goodwill) $126.23B.
- 2025-09-28: Intangible Assets, Gross (Excluding Goodwill) $122.66B.
| Period end | Intangible Assets, Gross (Excluding Goodwill) | Intangible Assets, Gross (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-28 | $121.98B 10-Q · filed 2026-08-04 | |
| 2026-03-29 | $126.42B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $126.23B 10-Q · filed 2026-08-04 | |
| 2025-09-28 | $122.66B 10-Q · filed 2025-11-04 | |
| 2025-06-29 | $123.22B 10-Q · filed 2025-08-05 | |
| 2025-03-30 | $122.75B 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $122.96B 10-K · filed 2026-02-26 | |
| 2024-09-29 | $126.49B 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $126.61B 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $126.98B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $127.73B 10-K · filed 2025-02-27 | |
| 2023-10-01 | $101.68B 10-Q · filed 2023-11-08 | |
| 2023-07-02 | $101.77B 10-Q · filed 2023-08-09 | |
| 2023-04-02 | $101.18B 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $101.92B 10-K · filed 2024-02-22 | |
| 2022-10-02 | $85.67B 10-Q · filed 2022-11-09 | |
| 2022-07-03 | $86.14B 10-Q · filed 2022-08-10 | |
| 2022-04-03 | $86.36B 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $80.98B 10-K · filed 2023-02-23 | |
| 2021-10-03 | $81.85B 10-Q · filed 2021-11-12 | |
| 2021-07-04 | $82.12B 10-Q · filed 2021-08-12 | |
| 2021-04-04 | $81.82B 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $80.83B 10-K · filed 2022-02-24 | $81.33B 10-K · filed 2021-02-25 |
| 2020-09-27 | $99.14B 10-Q · filed 2020-11-05 | |
| 2020-06-28 | $100.21B 10-Q · filed 2020-08-06 | |
| 2020-03-29 | $100.20B 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $82.88B 10-K · filed 2021-02-25 | $100.41B 10-K · filed 2020-02-27 |
| 2019-09-29 | $102.93B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $95.86B 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $95.82B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $95.95B 10-K · filed 2020-02-27 | |
| 2018-09-30 | $105.48B 10-Q · filed 2018-11-08 | |
| 2018-07-01 | $105.75B 10-Q · filed 2018-08-09 | |
| 2018-04-01 | $106.15B 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $105.77B 10-K · filed 2019-02-28 | |
| 2017-10-01 | $105.88B 10-Q · filed 2017-11-09 | |
| 2017-07-02 | $105.83B 10-Q · filed 2017-08-10 | |
| 2017-04-02 | $105.41B 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $104.33B 10-K · filed 2018-02-22 | |
| 2016-10-02 | $105.34B 10-Q · filed 2016-11-10 | |
| 2016-07-03 | $93.87B 10-Q · filed 2016-08-11 | |
| 2016-04-03 | $89.58B 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $89.40B 10-K · filed 2017-02-23 | |
| 2015-09-27 | $91.75B 10-Q · filed 2015-11-05 | |
| 2015-06-28 | $80.83B 10-Q · filed 2015-08-06 | |
| 2015-03-29 | $80.86B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $81.55B 10-K · filed 2016-02-29 | |
| 2014-09-28 | $82.48B 10-Q · filed 2014-11-06 | |
| 2014-06-29 | $82.60B 10-Q · filed 2014-08-07 | |
| 2014-03-30 | $82.40B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $82.50B 10-K · filed 2015-02-27 | |
| 2013-09-29 | $82.45B 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $82.36B 10-Q · filed 2013-08-09 | |
| 2012-12-31 | $83.38B 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |